Login / Signup

A Phase II study of ERK inhibition by ulixertinib (BVD-523) in Metastatic Uveal Melanoma.

Elizabeth I BuchbinderJustine V CohenGiuseppe TarantinoChristine G LianDavid R LiuRizwan HaqFrank Stephen HodiDonald P LawrenceAnita Giobbie-HurderDeborah KnoerzerRyan J Sullivan
Published in: Cancer research communications (2024)
ERK inhibition with ulixertinib (BVD-523) did not demonstrate activity in patients with metastatic uveal melanoma. The toxicities observed were consistent with what would be expected with MAPK pathway inhibition.
Keyphrases
  • phase ii study
  • signaling pathway
  • pi k akt
  • cell proliferation
  • squamous cell carcinoma
  • small cell lung cancer
  • oxidative stress
  • open label
  • randomized controlled trial
  • locally advanced
  • clinical trial
  • skin cancer